Proactive Investors - Run By Investors For Investors
Why invest in GDR?

Molecular diagnostics specialist Genedrive has hepatitis landmark in sight

Regulatory sign-off will fire the starting pistol on the commercial launch in Europe
Molecular diagnostics specialist Genedrive has hepatitis landmark in sight
The company has developed a quick and cheap test for Hepatitis-C

Genedrive PLC (LON:GDR) is nearing a landmark for its breakthrough rapid diagnostic for Hepatitis-C with the AIM-listed group ready to submit its breakthrough for regulatory approval.

The receipt of CE IVD certification under the EU Medical Devices Directive would green-light the commercialisation of the product in the European Union.

The application for CE Marking will be supported by the recent “excellent” performance data from a clinical validation study carried out at Institut Pasteur, in Paris, and Queen's Medical Centre, Nottingham.

Simple and speedy

Genedrive’s HCV assay for Hep-C provides on-the-spot results in just 90 minutes direct from a very small plasma sample.

READ: The latest Capital Market research on Genedrive

The trials revealed the technology was highly accurate and performed well against the best-in-class device.

“Application for CE Marking for the Genedrive HCV assay is a significant step in our development of a decentralised and qualitative molecular HCV test, which could be the first of its kind to market,” said David Budd, Genedrive chief executive.

“As we go through this process, we look forward to updating the market with our commercial partnership arrangements and target geographies for initial product introductions.”

Molecular diagnostics 

Genedrive describes itself as a molecular diagnostics company.

It is developing and commercialising a low cost, rapid, versatile, simple to use and robust “point of need” system that accurately picks up infectious diseases.

The Genedrive platform and its MTB/RIF test for tuberculosis have already launched in India.

As mentioned above the HCV test has undergone rigorous and successful testing with researchers in Paris and Nottingham ahead of the start of sales in the EU.

The studies demonstrated an overall sensitivity (accurate diagnosis) of greater than 99% and specificity (people don’t have disease) of 100% over a 955 sample cohort compared to the Abbott Molecular RealTime HCV Viral Load Assay.

The test was aimed decentralised use in areas with limited or non-existent health care infrastructure.


The assay used only a small amount of human plasma, eliminating the need for a separate RNA viral extraction process, and yielded results within 90 minutes.

Professor William Irving, Professor of Virology at Queen’s Medical Centre, said: "The diagnostic and treatment landscape for HCV has changed rapidly in recent years, and with the introduction of direct acting antivirals, there is a real opportunity to tackle the global burden of Hepatitis-C.

“Accurate, decentralised diagnostics, like Genedrive HCV, promise to be a big step forward in addressing the challenges associated with identifying and diagnosing those living with HCV infection and to give them access to this new and effective therapy."

Register here to be notified of future GDR Company articles
View full GDR profile View Profile

Genedrive PLC Timeline

Related Articles

May 03 2017
The hybrid pharma services and drug development group has hit some key milestones over this year as trial results are eyed.
Novogen: Access latest PPT from Proactive's CEO Sessions
April 13 2017
Dr James Garner talked clinical-stage programs with investors.
March 27 2017
Regulatory sign-off will fire the starting pistol on the commercial launch in Europe

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use